BRIDGEWATER, N.J., Nov. 7 /PRNewswire-FirstCall/ -- The Sanofi-aventis Group announced today that it has signed an agreement to move its U.S. headquarters from its current location at Somerset Corporate Center in Bridgewater to 55 Corporate Drive, also in Bridgewater, to combine the headquarters activities into one location and to support future growth. Financial details of the agreement were not disclosed.
The move is scheduled to begin in December 2005. The three-building complex at 55 Corporate Drive is situated on 150 acres on Route 206 near Interstates 287 and 78. The current plans call for a total reconfiguration of the interior space of the existing buildings. Full occupancy of the approximately 670,000 square feet is expected by the end of 2006.
A joint venture between The Gale Company, SL Green and a client of Principal Real Estate Investors acquired the 55 Corporate Drive office complex from AT&T Corporation earlier this year.
“The new site was chosen because it can accommodate our business needs for a more flexible and integrated space,” says Tim Rothwell, President and CEO of sanofi-aventis U.S. “In addition, we wanted to remain in the Bridgewater vicinity to accommodate our more than 3,800 sanofi-aventis employees from various divisions who currently work in the area. The site was a perfect choice.”
Sanofi-aventis currently maintains three sites in Bridgewater; Somerset Corporate Center, Bridgewater Crossings and the Science & Medical Affairs (S&MA) campus facility. Following completion of the move, all U.S. Pharmaceutical Operations employees will be located at the new site. Somerset Corporate Center will house an expanded Sales Training Center, the Northeast Regional Sales Office, and Global employees. The S&MA Campus and the Bridgewater Crossings facilities will be dedicated to S&MA activities.
About sanofi-aventis
The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and in New York .
Sanofi-aventis Group subsidiaries in the United States include Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
Contact: Marc Greene, sanofi-aventis 212-551-4400 or 908-243-42643 Michael Beckerman, for The Gale Company 908-781-6420
sanofi-aventis
CONTACT: Marc Greene, sanofi-aventis, +1-212-551-4400 or +1-908-243-42643;or Michael Beckerman, for The Gale Company, +1-908-781-6420
Web site: http://www.sanofi-aventis.com/
Company News On-Call: http://www.prnewswire.com/comp/232375.html/
